Darwin Global Management Ltd. Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Darwin Global Management Ltd. acquired a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 163,681 shares of the company’s stock, valued at approximately $3,084,000. Nurix Therapeutics accounts for 0.3% of Darwin Global Management Ltd.’s holdings, making the stock its 6th largest holding.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Northern Trust Corp boosted its holdings in Nurix Therapeutics by 16.4% during the 4th quarter. Northern Trust Corp now owns 659,788 shares of the company’s stock valued at $12,430,000 after acquiring an additional 92,933 shares during the period. The Manufacturers Life Insurance Company increased its stake in Nurix Therapeutics by 2.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company’s stock worth $585,000 after buying an additional 642 shares during the period. Aquatic Capital Management LLC acquired a new stake in Nurix Therapeutics during the 4th quarter worth approximately $87,000. Lord Abbett & CO. LLC boosted its position in Nurix Therapeutics by 24.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 437,772 shares of the company’s stock valued at $8,248,000 after buying an additional 87,132 shares during the period. Finally, Voya Investment Management LLC grew its stake in shares of Nurix Therapeutics by 171.8% in the fourth quarter. Voya Investment Management LLC now owns 55,079 shares of the company’s stock worth $1,038,000 after acquiring an additional 34,811 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Stephens reissued an “overweight” rating and set a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Royal Bank of Canada lifted their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, April 2nd. JPMorgan Chase & Co. lowered their target price on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Finally, Morgan Stanley increased their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a report on Monday, February 3rd. Three equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $30.44.

Insider Transactions at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,690 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the sale, the insider now directly owns 55,937 shares of the company’s stock, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Houte Hans Van sold 2,811 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the transaction, the chief financial officer now directly owns 39,549 shares in the company, valued at $785,047.65. This represents a 6.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock worth $213,449 over the last ninety days. 7.40% of the stock is currently owned by company insiders.

Nurix Therapeutics Stock Down 0.8 %

NRIX opened at $11.47 on Tuesday. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $29.56. The business has a 50 day moving average price of $12.47 and a two-hundred day moving average price of $18.27. The company has a market cap of $874.43 million, a PE ratio of -3.97 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.05. The company had revenue of $18.45 million for the quarter, compared to analysts’ expectations of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period in the previous year, the company posted ($0.76) EPS. As a group, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.